Decreased acylcarnitine content improves insulin sensitivity in experimental mice models of insulin resistance

Pharmacol Res. 2016 Nov;113(Pt B):788-795. doi: 10.1016/j.phrs.2015.11.014. Epub 2015 Nov 24.

Abstract

The important pathological consequences of insulin resistance arise from the detrimental effects of accumulated long-chain fatty acids and their respective acylcarnitines. The aim of this study was to test whether exercise combined with decreasing the content of long-chain acylcarnitines represents an effective strategy to improve insulin sensitivity in diabetes. We used a novel compound, 4-[ethyl(dimethyl)ammonio]butanoate (methyl-GBB), treatment and exercise to decrease acylcarnitine contents in the plasma and muscles in the insulin resistance models of high fat diet (HFD) fed C57BL/6 mice and db/db mice. The methyl-GBB treatment induced a substantial decrease in all acylcarnitine concentrations in both fed and fasted states as well as when it was combined with exercise. In the HFD fed mice methyl-GBB treatment improved both glucose and insulin tolerance. Methyl-GBB administration, exercise and the combination of both improved insulin sensitivity and reduced blood glucose levels in db/db mice. Methyl-GBB administration and the combination of the drug and exercise activated the PPARα/PGC1α signaling pathway and stimulated the corresponding target gene expression. Insulin insensitivity in db/db mice was not induced by significantly increased fatty acid metabolism, while increased insulin sensitivity by both treatments was not related to decreased fatty acid metabolism in muscles. The pharmacologically reduced long-chain acylcarnitine content represents an effective strategy to improve insulin sensitivity. The methyl-GBB treatment and lifestyle changes via increased physical activity for one hour a day have additive insulin sensitizing effects in db/db mice.

Keywords: Acylcarnitine; Diabetes; Energy metabolism; Exercise; Fatty acid oxidation; Novel treatment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Blood Glucose / drug effects
  • Carnitine / analogs & derivatives*
  • Carnitine / blood
  • Carnitine / metabolism
  • Diabetes Mellitus / blood
  • Diabetes Mellitus / drug therapy
  • Diabetes Mellitus / metabolism
  • Diabetes Mellitus, Experimental / blood
  • Diabetes Mellitus, Experimental / drug therapy
  • Diabetes Mellitus, Experimental / metabolism
  • Diet, High-Fat / adverse effects
  • Disease Models, Animal
  • Fatty Acids / metabolism
  • Gene Expression / drug effects
  • Glucose / metabolism
  • Insulin / metabolism*
  • Insulin Resistance / physiology*
  • Lipid Metabolism / drug effects
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Muscles / drug effects
  • Muscles / metabolism
  • PPAR alpha / metabolism
  • Physical Conditioning, Animal / physiology*
  • Quaternary Ammonium Compounds / pharmacology
  • Signal Transduction / drug effects
  • gamma-Aminobutyric Acid / analogs & derivatives
  • gamma-Aminobutyric Acid / pharmacology

Substances

  • Blood Glucose
  • Fatty Acids
  • Insulin
  • PPAR alpha
  • Quaternary Ammonium Compounds
  • acylcarnitine
  • methyl-gamma-butyrobetaine
  • gamma-Aminobutyric Acid
  • Glucose
  • Carnitine